ArticleESMO open2018

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable

Beatrice Borelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.